STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #355 by analyst upside · 2026-08-13
IMRX
Immuneering Corporation
Healthcare · Market Cap $328M · P/E 0x
ANALYST PRICE TARGET
+260.0%
implied upside to consensus target
Current Price $5.07
Consensus Target $18.25
Bull Target $30.0
Bear Target $12.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
0
Sell
0
52-Week Low $2.9
52-Week High $10.08
YTD Return -23.4%
FUNDAMENTALS
Market Cap $328M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.98
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.9
52-Week High $10.08
Current Price $5.07
Bear Target $12.0
Bull Target $30.0
● Now $5.07 ● Target $18.25
TRADING DATA
Avg Volume 1.5M
YTD Return -23.4%
Analyst Count 8
Consensus Buy
Upside to Target +260.0%
Last Updated 2026-08-13

ANALYST SUMMARY

Immuneering Corporation (IMRX) is currently trading at $5.07 with a Wall Street consensus price target of $18.25, implying potential upside of 260.0% over the next 12 months. 8 analysts currently cover IMRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $12.0.

IMRX operates in the Healthcare sector with a market capitalisation of $328M. The stock is down 23.4% year-to-date and is currently trading near the lower end of its 52-week range of $2.9 – $10.08.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IMRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-05-19 33% win rate (6 calls)
Needham reit
Buy → Buy 2026-03-09 20% win rate (5 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-11-13 33% win rate (6 calls)
Leerink Partners ● Initiated
Outperform 2025-10-31 29% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-09-30 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-09-26 33% win rate (6 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-09-25 14% win rate (7 calls)
Needham - Reiterated
Buy → Buy 2025-09-15 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →